Check out our most popular compounded medications! Get Started
Hydromorphone HCl 8 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer. This design allows for the gradual release of the active ingredient over an extended period, providing sustained therapeutic effects. This formulation is used to treat various types of pain including chronic, cancer, neuropathic, postoperative, and arthritis pain. The slow release mechanism also reduces dosing frequency, thereby improving patient compliance for medications requiring a controlled and prolonged release profile.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Hydromorphone HCl 8 mg Slow Release Capsules are a potent, long-acting opioid analgesic designed for the management of moderate to severe pain. This unique formulation incorporates Methocel E4M, a controlled-release polymer, which ensures a gradual and consistent release of the active ingredient over an extended period. This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and enhances patient compliance, particularly for medications that necessitate a controlled and prolonged release profile.
It is crucial to understand that this formulation is not intended for use as an immediate relief medication. It should only be used under the guidance and prescription of a healthcare provider. The Hydromorphone HCl 8 mg Slow Release Capsules are indicated for the treatment of moderate to severe pain in adults who have previously been treated with opioids.
This medication is not recommended for use in opioid-naive patients or those with respiratory depression, acute or severe bronchial asthma, or known or suspected paralytic ileus. Misuse of this medication can lead to addiction, overdose, or death, especially in individuals using it without a prescription or in higher doses than prescribed.
When taking Hydromorphone HCl 8 mg Slow Release Capsules, it is essential to adhere strictly to your healthcare provider's instructions. The medication should be taken exactly as prescribed, and the frequency of dosing should not be increased without medical advice. Sharing this medication with others is strictly prohibited due to its potential for abuse and addiction.
If you have any questions or concerns about Hydromorphone HCl 8 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. Our team of experienced compounding pharmacists is always ready to provide the necessary guidance and support.
Hydromorphone HCl 8 mg Slow Release Capsules, formulated with Methocel E4M, a controlled-release polymer, are designed to gradually release the active ingredient over an extended period. This formulation offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
These capsules may interact with other medications, supplements, or herbal products. It is crucial for patients to inform their healthcare provider of all medications, supplements, and herbal products they are currently taking before starting this medication. Patients should not start, stop, or change the dosage of any medications without consulting their healthcare provider.
Hydromorphone HCl 8 mg Slow Release Capsules may increase the risk of respiratory depression when taken with other medications that can cause respiratory depression, such as benzodiazepines, opioids, barbiturates, and alcohol. Patients should be monitored for signs of respiratory depression when taking this medication.
Similarly, these capsules may increase the risk of sedation when taken with other medications that can cause sedation, such as benzodiazepines, opioids, barbiturates, and alcohol. Patients should be monitored for signs of sedation when taking this medication.
Hydromorphone HCl 8 mg Slow Release Capsules may increase the risk of hypotension when taken with other medications that can cause hypotension, such as antihypertensives, diuretics, and vasodilators. Patients should be monitored for signs of hypotension when taking this medication.
These capsules may increase the risk of serotonin syndrome when taken with other medications that can cause serotonin syndrome, such as SSRIs, SNRIs, and MAOIs. Patients should be monitored for signs of serotonin syndrome when taking this medication.
Hydromorphone HCl 8 mg Slow Release Capsules may increase the risk of QT prolongation when taken with other medications that can cause QT prolongation, such as antiarrhythmics, antipsychotics, and tricyclic antidepressants. Patients should be monitored for signs of QT prolongation when taking this medication.
If you have any questions about the interactions of Hydromorphone HCl 8 mg Slow Release Capsules, please reach out to your healthcare provider.
Hydromorphone HCl 8 mg Slow Release Capsules are a potent opioid analgesic medication, specifically designed to provide relief from moderate to severe pain. The unique formulation of these capsules incorporates Methocel E4M, a controlled-release polymer. This innovative technology ensures a gradual and sustained release of the active ingredient, Hydromorphone HCl, over an extended period. This slow release mechanism offers consistent pain relief, reduces the need for frequent dosing, and enhances patient compliance, particularly for those requiring a medication with a controlled and prolonged release profile.
These capsules are intended for oral administration and can be taken with or without food, as per the instructions of your healthcare provider. It is crucial to adhere to the prescribed dosage, as deviations can lead to serious side effects. The capsules should not be crushed, chewed, or broken, as this can disrupt the controlled-release mechanism, causing a rapid release of the medication and increasing the risk of adverse effects.
Common side effects associated with Hydromorphone HCl 8 mg Slow Release Capsules may include nausea, vomiting, constipation, dizziness, and drowsiness. It is essential to promptly communicate with your healthcare provider if these side effects become severe or if you experience any other unusual symptoms. It is also important to note that this formulation is not recommended for patients with acute pain, as the slow release mechanism may not provide immediate pain relief.
However, it is of utmost importance to take the medication exactly as prescribed and to maintain open communication with your healthcare provider regarding any side effects or concerns. If you have any queries about this formulation, do not hesitate to seek professional advice.
Hydromorphone HCl 8 mg Slow Release Capsules are a compounded formulation designed to provide sustained pain relief over an extended period of time. These capsules are formulated with Methocel E4M, a type of controlled-release polymer, which allows for the gradual release of the encapsulated medication. This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
While primarily used for chronic pain management, Hydromorphone HCl 8 mg Slow Release Capsules can also be utilized for the treatment of various other types of pain, including musculoskeletal pain, fibromyalgia, and headaches. Additionally, it can be used to alleviate severe coughs and to mitigate the severity of opioid withdrawal symptoms.
It is crucial to note that Hydromorphone HCl 8 mg Slow Release Capsules are not intended for the treatment of acute pain, as they are not designed to provide rapid relief. Furthermore, these capsules should not be used to treat pain in patients who are not opioid-tolerant, due to the risk of serious side effects. When using Hydromorphone HCl 8 mg Slow Release Capsules for other types of pain, it is recommended to start with a low dose and gradually increase as needed, under the guidance of a healthcare professional.
Hydromorphone HCl 8 mg Slow Release Capsules is a medication that contains the active ingredient Hydromorphone HCl. It is formulated with Methocel E4M, a type of controlled-release polymer, designed to release the medication gradually over an extended period of time.
The controlled-release polymer, Methocel E4M, is designed to release the encapsulated medication gradually over an extended period of time. This offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
A slow-release formulation offers several benefits. It provides sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, especially for medications that require a controlled and prolonged release profile.
As this is a slow-release formulation, the frequency of dosing is typically reduced. However, the exact dosing schedule should be determined by your healthcare provider based on your specific medical condition and response to therapy.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
No, you should not crush or chew the capsules. Doing so can release all of the drug at once, increasing the risk of side effects. Also, it can damage the controlled-release feature of the capsule.
Common side effects may include constipation, nausea, vomiting, and dizziness. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Before starting this medication, tell your doctor or pharmacist of all the products you use, including prescription drugs, nonprescription drugs, and herbal products. They can check for any potential drug interactions.
No, you should avoid alcohol while taking this medication as it can increase the risk of serious side effects such as severe drowsiness/dizziness, difficulty waking up, and rare but very serious effects on breathing.
If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call emergency services immediately. Symptoms of overdose may include slow breathing, slow heartbeat, coma.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
